Stockscreener 앱 받기
0.9689
5.93%
-0.0611
시간 외 거래:
.99
0.0211
+2.18%
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing - MSN
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results - grafa.com
Humacyte stock rises on positive dialysis trial results By Investing.com - Investing.com India
Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure - Stock Titan
Humacyte’s bioengineered vessel shows benefit for women on dialysis - Investing.com UK
Humacyte’s bioengineered vessel shows benefit for women on dialysis By Investing.com - Investing.com Canada
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - The Manila Times
Bioengineered blood vessel helps women on dialysis avoid catheters longer - Stock Titan
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Director at Humacyte (NASDAQ: HUMA) receives 80,000 stock options grant - Stock Titan
Humacyte (HUMA) director receives 80,000 stock options at $1.08 exercise price - Stock Titan
Humacyte (HUMA) director receives 80,000 stock options at $1.08 strike price - Stock Titan
Humacyte (HUMA) CEO indirectly awarded 80,000 stock options via spouse - Stock Titan
[Form 4] Humacyte, Inc. Insider Trading Activity - Stock Titan
Humacyte (HUMA) director Keith Anthony Jones awarded 80,000 stock options at $1.08 - Stock Titan
Humacyte (HUMA) director receives grant of 80,000 stock options at $1.08 strike - Stock Titan
Director at Humacyte (NASDAQ: HUMA) granted 80,000 stock options - Stock Titan
Director at Humacyte (HUMA) receives grant of 80,000 stock options - Stock Titan
Humacyte (HUMA) director Emery N. Brown receives 80,000 stock options award - Stock Titan
H.C. Wainwright raises Humacyte stock price target on trial data - Investing.com UK
Humacyte prices $50M public offering of common stock at $1.05/share - MSN
H.C. Wainwright raises Humacyte stock price target on trial data By Investing.com - Investing.com Australia
Humacyte Announces Proposed Public Offering to Fund Commercialization of Symvess and Pipeline Development - Minichart
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
HUMA Maintained by HC Wainwright & Co. -- Price Target Raised to $4.00 - GuruFocus
Humacyte Announces Underwritten Public Equity Offering to Fund Growth - TipRanks
Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M - TradingView
Humacyte (HUMA) prices 47.6M-share stock sale at $1.05 to fund Symvess - Stock Titan
Humacyte (NASDAQ: HUMA) priced 47.6M shares at $1.05; Phase 3 met endpoint - Stock Titan
Why Is Humacyte Stock Falling Thursday? - Benzinga
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $4 - Moomoo
Humacyte stock falls despite positive Phase 3 data - scanx.trade
Biggest stock movers: ORCL, HUMA, and more - Seeking Alpha
Humacyte (HUMA) Phase 3 trial meets dialysis access endpoint - grafa.com
Humacyte, Inc. Announces Underwritten Public Offering of Common Stock - Quiver Quantitative
Biotech Humacyte prices $50M sale to fund Symvess, dialysis filing - Stock Titan
Humacyte prices $50 million public offering at $1.05 per share By Investing.com - Investing.com South Africa
Humacyte prices $50 million public offering at $1.05 per share - Investing.com
Humacyte stock falls 6% on public offering announcement - Investing.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Benzinga
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Yahoo Finance
Humacyte, Inc. Announces Proposed Public Offering of Common Stock - Yahoo Finance
HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses - Stocktwits
Humacyte reports positive Phase 3 trial results for dialysis access By Investing.com - Investing.com South Africa
Humacyte Announces Positive Phase 3 Dialysis Access Results - TipRanks
Stocks to Watch : Oracle, Oxford Industries, Humacyte, PureCycle Technologies - marketscreener.com
Humacyte launches public offering of common stock By Investing.com - Investing.com South Africa
Humacyte reports positive Phase 3 trial results for dialysis access - Investing.com
Humacyte launches public offering of common stock - Investing.com
2.60%
0.94%
자본화:
|
볼륨(24시간):